- Home
- MNKD
MNKD
MannKind Corporation
as 07-26-2024 4:00pm EST
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
| Founded: | 1991 | Country: | United States |
| Employees: | N/A | City: | DANBURY |
| Market Cap: | 1.2B | IPO Year: | 2004 |
| Target Price: | $8.00 | AVG Volume (30 days): | 2.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.17 - $6.04 | Next Earning Date: | 08-05-2024 |
| Revenue: | $224,599,000 | Revenue Growth: | 74.92% |
| Revenue Growth (this year): | 39.59% | Revenue Growth (next year): | 24.33% |
Stock Insider Trading Activity of MannKind Corporation (MNKD)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Binder Steven B. | MNKD | EVP Special Projects | May 17 '24 | Sell | $4.66 | 25,952 | $120,936.32 | 1,114,553 | SEC Form 4 |
| Thomson David | MNKD | EVP Genl Counsel & Secretary | May 17 '24 | Sell | $4.66 | 23,537 | $109,682.42 | 873,616 | SEC Form 4 |
| Binder Steven B. | MNKD | EVP Special Projects | May 10 '24 | Sell | $4.31 | 3,618 | $15,593.58 | 845,967 | SEC Form 4 |
| Thomson David | MNKD | EVP Genl Counsel & Secretary | May 10 '24 | Sell | $4.31 | 3,047 | $13,132.57 | 783,446 | SEC Form 4 |
| Castagna Michael | MNKD | Chief Executive Officer | Dec 14 '23 | Sell | $4.00 | 10,000 | $40,000.00 | 2,339,147 | SEC Form 4 |
| Castagna Michael | MNKD | Chief Executive Officer | Dec 14 '23 | Sell | $4.00 | 100,000 | $400,000.00 | 2,239,147 | SEC Form 4 |
| Castagna Michael | MNKD | Chief Executive Officer | Dec 14 '23 | Sell | $4.00 | 90,482 | $361,928.00 | 2,148,665 | SEC Form 4 |
| Castagna Michael | MNKD | Chief Executive Officer | Nov 1 '23 | Sell | $4.25 | 10,000 | $42,500.00 | 2,349,147 | SEC Form 4 |
Latest MannKind Corporation News
MNKD Breaking Stock News: Dive into MNKD Ticker-Specific Updates for Smart Investing
Simply Wall St.
10 days ago
Is There An Opportunity With MannKind Corporation's (NASDAQ:MNKD) 49% Undervaluation?
Zacks
10 days ago
All You Need to Know About MannKind (MNKD) Rating Upgrade to Buy
Zacks
10 days ago
Is MannKind (MNKD) Outperforming Other Medical Stocks This Year?
Zacks
10 days ago
MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue?
GlobeNewswire
a month ago
INHALE-3 Study Reveals Positive Readout in Head-to-Head Comparison of Inhaled Insulin vs. Usual Care in T1D; New Data Presented at American Diabetes Association’s 84th Scientific Sessions
Simply Wall St.
a month ago
Recent 5.2% pullback isn't enough to hurt long-term MannKind (NASDAQ:MNKD) shareholders, they're still up 327% over 5 years
GlobeNewswire
2 months ago
Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association’s 84th Scientific Sessions
MT Newswires
2 months ago
MannKind Agrees to Cross License Deal With Pulmatrix
Compare MNKD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MNKD MannKind Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.